WHERE WE INVESTED, 2019-2020





















RESEARCH FUNDING PROFILE

Province	Principal Investigator(s)	Project	Funding Period	Total Amount
	Dr. Yossef Av-Gay University of British Columbia, Vancouver	Targeting Intracellular and biofilm associated Mycobacterium abscessus for drug discovery	2017 - 2020	\$279,050
* * * *	Dr. Marcel Behr McGill University, Montreal	Non-tuberculous mycobacteria in CF - new chemistries for old targets	2018 - 2021	\$259,700
	Dr. Philip Britz-McKibbon McMaster University, Hamilton	Metabolomics for improved screening and prognosis of cystic fibrosis infants: translation of new biomarkers for resolving diagnostic dilemmas	2018 - 2021	\$300,000
	Drs. Silvia Cardona, Rebecca Davis, and Pingzhao Hu University of Manitoba, Winnipeg	Finding novel antibiotics against <i>Burkholderia cepacia</i> complex by genome-wide fitness and machine learning	2019 - 2022	\$300,000
	Dr. Charles Deber The Hospital for Sick Children, Toronto	Molecular basis of CF-causing mutations in CFTR	2017 – 2020	\$298,626
	Dr. Julie Forman-Kay The Hospital for Sick Children, Toronto	Structural insights into the phosphoregulatory elements of WT and mutant CFTR	2019 – 2022	\$300,000
	Dr. Tanja Gonska The Hospital for Sick Children, Toronto	Interrogation of the prevalence of intestinal inflammation in CF patients and its correlation to abdominal pain	2018 - 2020	\$198,189
* *	Dr. Ryszard Grygorczyk University of Montreal	Understanding the regulation of mucin release and rheology in cystic fibrosis	2016 – 2019 (no cost ext.)	\$213,231
* *	Dr. John Hanrahan McGill University, Montreal	Solute carrier 26 family transporters as therapeutic targets in CF	2019 – 2022	\$300,000
* *	Dr. John Hanrahan McGill University, Montreal	Primary Airway Cell Biobank	2017 – 2019 (no cost ext.)	\$112,500
	Drs. David Heinrichs and Ronald Flannagan University of Western Ontario, London	Subversion strategies of MRSA in the macrophage	2017 - 2020	\$297,600
	Dr. Jim Hu The Hospital for Sick Children, Toronto	Enhancing the efficiency of CRISPR-mediated gene correction for cystic fibrosis therapy	2018 - 2021	\$300,000
⊕ **	Dr. Juan lanowski University of Saskatchewan, Saskatoon	CF airways fail to clear inhaled pathogens due to abnormal submucosal glands function and hyperactive Na ⁺ reabsorption	2018 – 2021	\$287,771

	Dr. Zongchao Jia Queen's University, Kingston	Inhibition of polyphosphate kinase in <i>P. aeruginosa</i> as a novel antimicrobial strategy for CF therapeutics	2019 – 2022	\$300,000
	Dr. Stephen Juvet University Health Network, Toronto	Control of the early-post-transplant immunological milieu to prevent lung allograft rejection	2018 – 2020	\$200,000
	Dr. Rees Kassen University of Ottawa	Evolutionary genetics of chronic infection by <i>Pseudomonas</i> aeruginosa in the cystic fibrosis lung	2017 – 2020	\$297,895
	Dr. Shaf Keshavjee University Health Network, Toronto	Novel combined anti-fibrotic and IL-10 gene therapy to prevent post-transplant chronic lung allograft dysfunction	2019 – 2022	\$300,000
=	Dr. Paul Kubes University of Calgary	Understanding the interplay between alveolar macrophages and <i>P. aeruginosa</i> in the cystic fibrosis lung	2018 – 2021	\$300,000
3	Dr. Paul Linsdell Dalhousie University, Halifax	Conformational change opening and closing the CFTR channel	2017 – 2020	\$300,000
* *	Dr. Gergely Lukacs McGill University, Montreal	CFTR domain folding and misfolding	2019 – 2022	\$300,000
* *	2019 Senior Scientist Award 2019 Cathleen Morrison Research Impa	ct Award		
* *	Dr. Geneviève Mailhot CHU Sainte-Justine	Towards establishing vitamin D as a nutritional therapeutic in cystic fibrosis intestinal disease	2019 – 2022	\$299,960
* *	Dr. François Malouin University of Sherbrooke	New antibiotic combination for MRSA and <i>Pseudomonas</i> aeruginosa in cystic fibrosis	2018 – 2021	\$300,000
* *	Dr. Dao Nguyen McGill University, Montreal	Understanding host-pathogen interactions to improve eradication of initial <i>Pseudomonas aeruginosa</i> infections in CF	2018 – 2021	\$284,691
	Dr. Justin Nodwell University of Toronto & Dr. Marie Elliot McMaster University, Hamilton	Therapeutics for CF Pathogens	2017 - 2020	\$289,128
5	Dr. Michael Parkins University of Calgary	A comprehensive longitudinal cohort study of infection transmission in cystic fibrosis	2017 – 2020	\$299,982
4 4	Dr. Basil Petrof McGill University, Montreal	Addressing muscle wasting in cystic fibrosis	2017 – 2020	\$270,468
	Dr. Keith Poole Queen's University, Kingston	Identification and targeting of CF lung-driven antimicrobial resistance in <i>P. aeruginosa</i>	2018 – 2021	\$299,955
	Dr. Bradley Quon Centre for Heart Lung Innovation, Vancouver	PIPE-CF Biomarker Study	2017 – 2020	\$291,579
	Dr. Daniela Rotin The Hospital for Sick Children, Toronto	Use of lung organoids from CF patients to analyze response to ENaC inhibitors	2018 – 2021	\$299,984
* *	Dr. Donald Sheppard McGill University, Montreal	Development of therapeutic agents for <i>Pseudomonas</i> and <i>Aspergillus</i> lung disease in cystic fibrosis	2018 - 2021	\$273,834

	Dr. Anne Stephenson St. Michael's Hospital 2019 Robbie Award	International comparisons of clinical characteristics, health outcomes and survival between Canada, France, and Australia	2019 – 2022	\$255,194
	Dr. Anne Stephenson St. Michael's Hospital	Factors associated with declining health during adolescence and young adulthood in CF	2018 – 2019 (no cost ext.)	\$42,145
	Dr. Lisa Strug, The Hospital for Sick Children, Toronto	The genetic epidemiology of cystic fibrosis	2019 - 2022	\$300,000
	Dr. Michael Surette McMaster University, Hamilton	Microbiology of pulmonary exacerbations	2017 – 2020	\$285,000
* *	Drs. David Thomas and John Hanrahan McGill University, Montreal	Increasing trafficking of F508del-CFTR: a rational approach	2018 - 2021	\$300,000
	Drs. Manish Sadarangani, David Speert, Mark Chilvers and James Zlosnik University of British Columbia, Vancouver	Canadian <i>Burkholderia cepacia</i> complex Research and Referral Repository (CBCCRRR)	2017 – 2020	\$270,000
	Dr. Valerie Waters The Hospital for Sick Children, Toronto	Conducting a randomized controlled trial of prednisone in cystic fibrosis pulmonary exacerbations (PIPE Study)	2016 – 2019 (no cost ext.)	\$356,419
Partnersh	ips – Canadian Institutes of H	lealth Research (CIHR)		
Province	Principal Investigator(s)	Project	Funding Period	CF Canada Amount
* *	Dr. John Hanrahan McGill University, Montreal & Dr. Janet Rossant The Hospital for Sick Children, Toronto	Induced pluripotent stem cells for identification of novel drug combinations targeting cystic fibrosis lung and liver disease	2016 – 2019 (no cost ext.)	\$105,000
	Dr. Jonathan Rayment University of British Columbia	Antibiotic treatment of <i>Staphylococcus aureus</i> in stable patients with CF	2018 - 2021	\$148,800
9	CIHR Institute of Circulatory and Respirato	ory Health – CF Canada 2018 Early Career Investigator Award		
	Dr. Lori West University of Alberta, Edmonton	The Canadian Donation and Transplantation Research Program	2018 - 2021	\$60,000